Entrada Therapeutics (TRDA) EBT (2020 - 2026)

Entrada Therapeutics' EBT history runs 7 years deep, the most recent figure standing at -$39.7 million for Q1 2026.

• In Q1 2026, EBT fell 128.71% year-over-year to -$39.7 million; the TTM figure through Mar 2026 stood at -$165.2 million (down 793.67% YoY), while the FY2025 annual figure was -$142.8 million, down 314.82% from the prior year.
• EBT was -$39.7 million for Q1 2026 at Entrada Therapeutics, down from -$39.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $57.8 million in Q2 2024 to a low of -$43.5 million in Q3 2025.
• Historically, EBT has averaged -$11.7 million across 5 years, with a median of -$17.3 million in 2025.
• The sharpest annual moves came in 2024 and 2025: EBT jumped 910.98% in 2024, then slumped 5187.14% in 2025.
• A 5-year view of EBT shows it stood at -$24.6 million in 2022, then soared by 137.52% to $9.2 million in 2023, then plunged by 108.0% to -$739000.0 in 2024, then slumped by 5187.14% to -$39.1 million in 2025, then retreated by 1.55% to -$39.7 million in 2026.
• The last three EBT figures came in at -$39.7 million (Q1 2026), -$39.1 million (Q4 2025), and -$43.5 million (Q3 2025), per Business Quant data.